Organicell Regenerative Medicine, Inc.
OCEL · OTC
10/31/2024 | 10/31/2023 | 10/31/2022 | 10/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.09 | 0.05 | 0.10 | 0.12 |
| FCF Yield | -12.93% | -17.87% | -12.90% | -5.38% |
| EV / EBITDA | -1.99 | -1.81 | -3.46 | -4.62 |
| Quality | ||||
| ROIC | 324.33% | 1,235.02% | -303.96% | 696.62% |
| Gross Margin | 81.73% | 88.86% | 88.39% | 90.21% |
| Cash Conversion Ratio | 0.31 | 0.31 | 0.36 | 0.20 |
| Growth | ||||
| Revenue 3-Year CAGR | -10.72% | -6.62% | 28.55% | 48.70% |
| Free Cash Flow Growth | 34.76% | 44.30% | -28.52% | -59.14% |
| Safety | ||||
| Net Debt / EBITDA | 0.12 | 0.17 | 0.33 | -0.06 |
| Interest Coverage | 57.82 | -15.69 | -22.20 | -335.95 |
| Efficiency | ||||
| Inventory Turnover | 3.64 | 1.64 | 3.03 | 2.33 |
| Cash Conversion Cycle | 115.90 | 538.87 | -1,020.98 | -1,084.58 |